DR. ADITI PAI

Dr. SHANKAR S. GANVIT, Dr. AHIR HASMUKH DAHYABHAI, DR. ATUL KAMATH

Abstract

AIM- role of retrobulbar amphotericin to tackle mucormycosis. METHODS- Prospective randomised study of patients who were admitted with orbital mucormycosis. Amphotericin of dosage 3.5mg/ml was given via retrobulbar approach in the infero-medial and super-medial aspect of the globe after giving 2ml of lignocaine. consent and ethics commitee approval was obtained. Amphotericin was injected every 5th day for 4 doses & observed. RESULTS- 74 patients had orbital mucormycosis out of which 50 were given amphotericin. 28 had improvement while 12 underwent exenteration & remaining 10 succumbed to the disease. Conclusion- the second wave of covid-19 pandemic caused a havoc in India with many people being debilitated with mucormycosis. although various theories were given for the development and to tackle mucormycosis, retrobulbar amphotericin was tried and found to be effective in controlling orbital mucormycosis to some extent. cosmesis was a major issue for the patients post exenteration.

Full Text